<DOC>
	<DOCNO>NCT00372112</DOCNO>
	<brief_summary>The compound GW642444 previously find well tolerated significant side effect subject asthma healthy volunteer . This study ass safety tolerability GW642444 subject COPD order obtain information support dose broad population subject COPD</brief_summary>
	<brief_title>A Study To Assess The Safety And Tolerability Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>A multicentre , randomise , placebo-controlled , double-blind , 4-arm parallel-group , 2-week study evaluate safety , tolerability , pharmacodynamics pharmacokinetics GW642444H ( 100 administer daily morning via DISKUSâ„¢ dry-powder inhaler ) compare SEREVENT ( salmeterol ) ( 50mcg administer twice daily via DISKUS dry-powder inhaler ) placebo subject moderate COPD .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criterion : female must nonchildbearing potential moderately severe COPD Exclusion criterion : Subjects main diagnosis asthma subject poorly control COPD subject significant heart , renal , endocrine , psychiatric , immunological neurological disease .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease ( COPD )</keyword>
	<keyword>COPD</keyword>
</DOC>